PTO/SB/08A (08-00)

Approved for use through 10/31/2002 OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE re required to respond to a collection of information unless it contains a valid OMB control number Under the Paperwork Reduction

Substitute for Form 1449/A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary

Sheet of 3

Complete if Known						
Application Number 10/650,110						
Filing Date	August 26, 2003					
First Named Inventor	Yanhong Zhu					
Group Art Unit	1614					
Examiner Name	LESLIE A. ROYDS					
Attorney Docket Number	13131-0292 (44378-287574)					

U.S. PATENT DOCUMENTS									
Examiner Initials	Cite No.'	U.S. Patent Document Kind Code ¹ Number (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear				
UMC	1	6,037,458	Hirai et al.	03-14-2000					
12/12	2	6,080,778	Yankner et al.	06-27-2000					
A ANZ	3	6,127,370	Smith et al.	10-03-2000	_				
JAZ	4	6,440,387	Yankner et al.	08-27-2002					
1 Par	5	6,472,421	Wolozin	10-29-2002					
TAR	6	2001/0028895	Bisgaier et al.	10-11-2001	_				
LARZ	7	2002/0055529	Bisgaier et al.	05-09-2002	-				
NAC	8	2002/0081263	Yankner et al.	06-27-2002					
NAL	9	2002/0107173	Friedhoff et al.	08-08-2002					
JIMO.	10	2002/0183379	Yankner et al.	12-05-2002	-				
NAC	11	2002/0188012	Bisgaier et al.	12-12-2002	_				
JARL	12	2003/0018013	Dasseux et al.	01-23-2003					
ľ	,								
					· · · · · · · · · · · · · · · · · · ·				
				•					

				FORE	IGN PATENT DOCUMEN	TS		
Examiner Initials	Cite No. ¹	Office ³		ment Kind Code ³ (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	7*
JAR	13	wo	99/38498	Al	Warner-Lambert Company	08-05-1999		
LAQ.	14	wo	01/56579	Al	Esperion Therapeutics, Inc.	08-09-2001		
ine	15	wo	02/10768	A3	The Regents of the University of California	02-07-2002	-	
WAR	16	wo	02/30863	A2	Esperion Therapeutics, Inc.	04-18-2002	_	
URL	17	wo	02/062824	A3	Andrx Corporation	08-15-2002	•	
			\triangle					\Box
		L						
								1
			1					1
		1	1 / 4 /					
		X		\///				

Examiner FO Y-1UT 21 Date Signature Considered

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST\3). ⁴For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵King of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁸Applicant is to place a check mark here if English language translation is attached.

PTO/SB/08B (08-00)

Approved for use through 10/31/2002 OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction of information unless it contains a valid OMB control number

Substitute for Form 1449/A/PTO

INFORMATION DISCLOSSURE STATEMENT BY APPLICANT

(use as many sheets as necessary

Sheet 2 of 3

Complete if Known							
Application Number	Application Number 10/650,110						
Filing Date	August 26, 2003						
First Named Inv ntor	Yanhong Zhu						
Group Art Unit	1614						
Examiner Name	LESUEA ROYUS						
Attorney Docket Number	13131-0202 (44378-287574)						

		OTHER INFORMATION - NON PATENT LITERATURE DOCUMENTS	.]
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T²
	18	BARRES, BEN A., et al., Cholesterol - Making or Breaking the Synapse, Science, November 9, 2001, pp. 1296-1297, vol.	
WARE		294.	
	19	BURNS, M. et al., Use of in vivo Models to Study the Role of Cholesterol in the Etiology of Alzheimer's Disease, Neurochem 🕠	
NAR		Res, July 2003, pp. 979-86 (abstract only), vol. 28.	
	20	COOPER, J., Dietary Lipids in the Aetiology of Alzheimer's Disease: Implications for Therapy, Drugs Aging, 2003, pp. 399-418	
LAR		(abstract only), vol. 20, no. 6.	
	21	GLODE, TODD E., et al., Cholesterol Modulation as an Emerging Strategy for the Treatment of Alzheimer's Disease, Drug	
MA		Discovery Today, Oct. 15, 2001, pp. 1049-1055 (abstract only), vol. 6, no. 20.	
	22	KOUDINOV, A.R., et al., Alzheimer's Amyloid Beta Interaction with Normal Human Plasma High Density Lipoprotein:	
HAR		Association with Apolipoprotein and Lipids, Clin Chim Acta, February 23, 1998, pp. 75-84 (abstract only), vol. 270, no. 2.	
	′23	KOUDINOV, A.R., et al., Alzheimer's Soluble Amyloid Beta Protein is Secreted by HepG2 Cells as an Apolipoprotein, Cell Biol	
LAR		Int., May 1997, pp. 265-71 (abstract only), vol. 21, no. 5.	
	24	KOUDINOV, A.R., et al., Biochemical Characterization of Alzheimer's Soluble Amylold Beta Protein in Human Cerebrospinal	
. /		Fluid: Association with High Density Lipoproteins, Biochem Biophys Res Commun., June 25, 1996, pp. 592-7 (abstract only),	
MAR		vol. 223, no. 3.	
	25	KOUDINOV, ALEXEI R., et al., Cholesterol's Role in Synapse Formation, Science, November 9, 2001, pp. 2213, vol. 294.	
MAK			
	26	KOUDINOVA, N.V., et al., Amyloid Beta, Neural Lipids, Cholesterol and Alzheimer's Disease, Soc. Neuroscience Abstract	
JAR		Viewer and Itinerary Planner, Nov. 2-7, 2002, pp. Abstract No. 21.10, vol. 2002.	
/	27	LIPID SCIENCES, Lipid Technology, http://www.lipidsciences.com/technology.html, August 25, 2001, pp. 1-4.	
NAR			
	28	MAUCH, DANIELA H., et al., CNS Synaptogenesis Promoted by Glia-Derived Cholesterol, Science, November 9, 2001, pp.	
LEAL	-	1354-1357, vol. 294.	
/	29	REFOLO, L.M., et al, Cholesterol Metabolism: A Potential Target for Alzheimer's Disease Therapy, Soc. Neuroscience	
LAR		Abstracts) 2001, pp. 1518 , vol. 27, no. 2.	
7	30	YOSHIDOME, HIROAKI et al., Serum Amyloid A and P Protein Levels are Lowered by Dextran Sulfate Cellulose Low-Density	
LAR		Lipoprolein Apheresis, Artif Organs, 1998, pp 144-148, vol. 22, no. 2.	

Examiner Signature	X	M'	\mathcal{M}	149		Date Considered	16JULY07	

Unique citation designation number. Applicant is to place a check mark here if English language translation is attached.

PTO/SB/08B (08-00)
Approved for use through 10/31/2002 OMB 0851-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

DEC 0 4 2003 Under the Paperwork

Substitute for Form 1449/A/PTO

Sheet 3

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary

		mation unless it contains a valid OMB control number nplete if Known		
	Application Number	10/650,110		
) E	Filing Date	August 26, 2003		
RE	First Named Inventor	Yanhong Zhu		
ĮT	Group Art Unit	1614		
	Examiner Name	LESLIE A. ROYDS		
	Attorney Docket Number	13131-0292 (44378-287574)		

		OTHER INFORMATION - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T²
LAD	31	Zetia (ezetimibe), http://www.zetia.com/ezetimibe/zetia/hcp/product_highlights/index.jsp, July 18, 2003, pp. 1-2.	
1910	32	Zetia: Complements Statin with a Unique Mechanism.	-
TAR	32	http://www.zetia.com/ezetimibe/zetia/hcp/mechanism_of_action/index.jsp, July 18, 2003, pp. 1-2	
			-
•			
-			
Examiner		Date INJULY D7	•

Signature

Considered

I MYNTA D+

eck mark here if English language translation is attached. Unique citation designation number.

PTO/SB/08A (08-00)
Approved for use through 10/31/2002 OMB 0851-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE fork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for Forms

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary

Sheet 1

Coi	mplete if Known
Application Number	10/650,110
Filing Date	August 26, 2003 ·
First Named Inventor	Yanhong Zhu
Group Art Unit	1646-1614
Examiner Name	Not yet Assigned LESUEA, ROYDS
Attorney Docket Number	13131-0292 (44378/287574)

	U.S. PATENT DOCUMENTS									
		U.S. Patent		Name of Colorina as Application	Date of Publication of Cited Document	Pages, Columns, Lines Relevant Passages or				
Examiner Initials	Cite No.1	Number	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	MM-DD-YYYY	Figures Appear				
HAIL	1	3,647,624		Evenson	03-07-1972					
LNR	2	3,958,939		Jones	05-25-1976					
W1902	3	3,983,008		Shinozaki et al.	09-28-1976					
MARK	4	3,989,466		Pan	11-02-1976	_				
IMZ	5	4,025,423		Stonner et al.	05-24-1977		•			
ITAL	6	4,103,685		Lupien et al.	08-01-1978					
JANE	7	4,124,509		Iijima et al.	11-07-1978					
V DANL	8	4,234,317		Lucas et al.	11-18-1980					
	9	4,235,602		Meyer et al.	11-25-1980					
JAR	10	4,258,010		Rozsa et al.	03-24-1981					
UAL	11	4,350,156		Malchesky et al.	09-21-1982					
UAA2	12	4,391,711		Jackson et al.	07-05-1983					
UAX	13	4,399,217		Holmquist et al.	08-16-1983					
APR	14	4,402,940		Nose et al.	09-16-1983					
1/42	15	4,435,289		Breslau	03-06-1984					
MAG	16	4,463,988		Bouck et al.	08-07-1984					
UAXZ	17	4,481,189		Prince	11-06-1984					
VAC	18	4,522,809		Adamowicz et al.	06-11-1985					
MAL	19	4,540,401		Marten	09-10-1985					
TAR	20	4,540,573		Neurath et al.	09-10-1985					
IAL	21	4,591,505	·	Prince	05-27-1986					
UAL	22	4,613,501		Horowitz	09-23-1986					
UPA	23	4,615,886		Purcell et al.	10-07-1986					
UAL	24	4,643,718		Marten	02-17-1987					
LOL	25	4,645,512		Johns	02-24-1987					
LA2	26	4,647,280		Maaskant et al.	03-03-1987		•			
LAL	27	4,648,974		Rosskopf et al.	03-10-1987					
IAC	28	4,668,398		Silvis	05-26-1987					
NOL.	29	4,671,909		Torobin	09-09-1987					
VAR	30	4,676,905		Nagao et al.	06-30-1987	4				
NAC	31	4,677,057		Curtiss et al.	06-30-1987					
NAL	32	4,680,320		Uku et al.	07-14-1987					
IAL	33	4,696,670		Ohnishi et al.	09-29-1987		<u> </u>			
UNL	34	4,775,483		Mookerjea et al.	10-04-1988					
UAR	35	4,832,034		Pizziconi et al.	05-23-1989					
JAL	36	4,836,928	\wedge	Aoyagi et al.	06-06-1989					
IAR	37	4,879,037	100	Utzinger	_ 11-07-1989					

16 JULY 07-Examiner Date Signature Considered

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached

IDS Filed Aug. 18,2004

Approved for use through 10/31/2002 OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for Form 1449/A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary

Sheet 2 of 9

ed to respond to a conecil	dir or information direas it contains a valid direct territori				
	Complete if Known				
Application Numb	per 10/650,110				
Filing Date	August 26, 2003				
First Named Inve	ntor Yanhong Zhu				
Group Art Unit	-1646 IbIU				
Examiner Name	Not yet Assigned LESUIEA ROYDS				
Attorney Docket N	umber 13131-0292 (44378/287574)				

U.S. PATENT DOCUMENTS											
Examiner Initials	Cite No.1	U.S. Patent	Document Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear					
LAYL.	38	4,895,558	1	Cham	01-23-1990						
M	39	4,908,354		Seidel et al.	03-13-1990						
M	40	4,909,940		Horowitz et al.	03-20-1990						
AL	41	4,909,942		Sato et al.	03-20-1990						
LAL	42	4,923,439		Seidel et al.	05-08-1990						
ARK	43	4,935,204		Seidel et al.	06-19-1990						
PL	44	4,966,709		Nose et al.	10-30-1990						
pl	45	4,970,144		Fareed et al.	11-13-1990						
PAL	46	5,026,479		Bikson et al.	06-25-1991						
AR	47	5,080,796		Nose et al.	01-14-1992						
MR	48	5,089,602		Isliker et al.	02 10 1002						
MR	49	5,112,956		Tang et al.	05-12-1992						
Agra	50	5,116,307		Collins	05-26-1992						
ME	51	5,126,240		Curtiss	03-30-1992						
MR	52	5,128,318		Levine et al.	07-07-1992						
ARR	53	5,152,743		Gorsuch et al.	10-06-1992						
AR	54	5,187,010		Parham et al.	02-16-1993						
UPL	55	5,203,778		Boehringer	04-20-1993	·					
AL	56	5,211,850		Shettigar et al.	05-18-1993						
Al	57	5,236,644		Parham et al.	08-17-1993						
AR	58	5,256,767		Salk et al.	10-26-1993						
MR	59	5,258,149		Parham et al.	11-02-1993						
M	60	5,279,540		Davidson	01-18-1994						
MAR	61	5,301,694		Raymond et al.	04-12-1994	:					
M	62	5,354,262		Boehringer et al.	10-11-1994						
Unit	63	5,391,143		Kensey	02-21-1995						
HR	64	5,393,429		Nakayama et al.	02-28-1995						
LIDIR	65	5,401,415		Rauh et al.	03-28-1995						
MOV.	66	5,401,466		Foltz et al.	03-28-1995						
DE	67	5,418,061		Parham et al.	05-23-1995						
AL	68	5,419,759		Naficy	05-30-1995						
NAF	69	5,424,068		Filip	06-13-1995						
JAR	70	5,476,715		Otto	12-19-1995						
UAR	71	5,484,396		Naficy	01-16-1996						
VAIL	72	5,496,637 /		Parham et al.	03-05-1996						
VAR	73	5,523,096	· · · · · · · · · · · · · · · · · · ·	Okarma et al.	06-04-1996						
INL	74	5,634,893	\ 	Rishton	06-03-1997						
NA	75	5,637/224	1 1-1	Sirkar et al.	06-10-1997						

Examiner Signature Date Considered UJVLY 07

'Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached.

IDS Filed Aug. 18, 2004

Approved for use through 10/31/2002 OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for Form 1449/A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary

Sheet 3

Complete if Known							
Application Number	10/650,110						
Filing Date	August 26, 2003						
First Named Inventor	Yanhong Zhu						
Group Art Unit	-1646- 1614						
Examiner Name	Not yet Assigned LESUEA ROYD						
Attorney Docket Number	13131-0292 (44378/287574)						

U.S. PATENT DOCUMENTS								
Examiner	Cite No.1	U.S. Patent	Document Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
Initials	76	5,652,339	(7) (3.5.1.1.5)	Lerch et al.	07-29-1997			
MAL	77	5,679,260		Boos et al.	10-21-1997			
JAI	78	5,698,432		Oxford	12-16-1997			
MR	79	5,707,673		Prevost et al.	01-13-1998			
1210 121	80	5,719,194		Mann et al.	02-17-1998			
WAL	81	5,744,038		Cham	04-28-1998			
HAL	82	5,753,227		Strahilevitz	05-19-1998			
WAL	83	5,853,725		Salk et al.	12-29-1998			
NAL	84	5,855,782		Falkenhagen et al.	01-05-1999			
Mar	85	5,858,238		McRea et al.	01-12-1999			
VAL	86	5,877,005		Castor	03-02-1999			
LAIL	87	5,885,578		Salk et al.	03-23-1999			
JAN	88	5,895,650		Salk et al.	04-20-1999			
IAL	89	5,911,698		Cham	06-15-1999			
TAL	90	5,916,806		Salk et al.	06-29-1999			
W/2	91	5,919,369		Ash	07-06-1999			
DIL	92	5,928,930		Salk et al.	07-27-1999			
LAR	93	5,948,441		Lenk et al.	09-09-1999			
NAL	94	5,962,322		Kozarsky et al.	10-05-1999			
IAL	95	5,980,478		Gorsuch et al.	11-09-1999			
IAL	96	6,004,925	-	Dasseux et al.	12-21-1999			
NAR	97	6,017,543		Salk et al.	01-25-2000			
LAL	98	6,022,333		Kensev	02-28-2000			
JAK -	99	6,037,323		Dasseux et al.	03-14-2000			
JAIL	100	6,039,946		Strahilevitz	03-21-2000			
LAR	101	6,046,166		Dasseux et al.	04-04-2000			
LW.	102	6,136,321		Barrett et al.	10-24-2000			
LAL	103	6,139,746	-	Kopf	10-31-2000			
LAR	104	6,156,727		Garber et al.	12-05-2000			
Jak	105	6,171,373	~	Park et al.	01-09-2001			
AR	106	6,193,891		Kent et al.	02-27-2001			
LAR	107	6,264,623		Strahilevitz	07-24-2001			
AL	108	6,309,550		Iverson et al.	10-30-2001			
MAL	109	6,337,368		Kobayashi et al.	01-08-2002			
LAD	110	6,605,588		Lees et al.	08-12-2003			
MAL	111	6,706,008		Vishnoi et al.	03-16-2004			
		- 1		7 13 110 7 0 1 11	_			
-		1 1		_		_		
		 	1 1	h - /	_			

16JULY 07 Examiner Date Signature Considered

'Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached.

IDS Filed Aug. 18, 2004
PTO/SB/08A (08-00)

Approved for use through 10/31/2002 OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for Form 1449/A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary

Sheet 4

Complete if Known								
Application Number	10/650,110							
Filing Date	- August 26, 2003 Yanhong Zhu							
First Named Inventor								
Group Art Unit	1646-1614							
Examiner Name	Not yet Assigned LESUEA. ROYDS							
Attorney Docket Number	13131-0292 (44378/287574)							

			·····	F	ORE	IGN PATENT DOCUMEN	TS		
Examiner			Foreign Patent D	ocument			Date of Publication of	Pages, Columns, Lines, Where	T
Initials	Cite No.1	Office,	Number ⁴	Kind Cod (if know		Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	Relevant Passages or Relevant Figures Appear	
UAR	112	CA	1 271 708			Schweiz Serum & Impfinst	07-17-1990		┸
,	113	CN	1189378			Central Blood Ban	08-05-1998	Abstract Only	
WAR		1	·			ChangChun CI			_
MAR	114	DE	29 44 138		Al	Technicon Gmbh	06-11-1981		\perp
LAR	115	DE	31 18 072		Αl	Heuck	11-25-1982		
LAR	116	DE	32 13 390		Äl	Schurek, et al.	10-20-1983		L
LAR	117	DE	33 10 263		Al	Fresenius AG	09-27-1984		L
LAR-	118	EP	0 036 283		A2	Davy Mckee Minerals & Metals	09-23-1981		
UNC	119	EP	0 267 471		Al	Pennwalt Corporation	05-19-1988		\top
140	120	FR	2 571 971		Al	Haas Thierry	04-25-1986		1
LAR.	121	JP	127104	•	T	Shinriyoushiyo	01-10-1980		T
42	122	JP	277303			Tenkaidou	10-26-1993		1
400	123	SU	1116396		A	Mosc. Med Inst. Pirog	09-30-1984		
1.00	124	SU	1204224		A	Kazan Chem. Tech Inst.	01-15-1986		1
DATE	125	SU	1752187		A3	Sigalov	07-30-1992	Abstract only	#
IAL	126	wo	88/09345		A1	The Rogosin Institute	12-01-1988		+
in	127	wo	95/03840		A1	The University of Queensland	02-09-1995		1
UANC.	128	wo	01/45718		Al	Aruba International Pty Ltd.	06-28-2001		+
DATAK	120	 	01/45/10		 -	7 trade trad	00 20 200.		士
		 							7
		 			 				+
-	-	 			 -				+
							 		+
									+
	<u> </u>	·							+
		ļ							+
		ļ							+
		ļ			<u> </u>				┿
		ļ							+
									+
		ļ			_			·	+
									4
									4
	•				<u> </u>				4
									┸
									1
		1		\sim					\perp
									\perp
-		in		7/1					_
Examiner Signature		TAX	CALL DOLL	XXI	N	M	Date Considered	16JULY07	

'Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached.

TDS Filed Acg. 18 | 2004 PTO/\$B/08B (08-00) Approved for use through 10/31/2002 OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE to a collection of information unless it contains a valid OMB control number

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for Form 1449/A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary

Sheet 5 of 9

red to respond to a collection of infor	mation diffess it contains a valid Ovid control fidinger						
Con	mplete if Known						
Application Number 10/650,110							
Filing Date	August 26, 2003						
First Named Inventor	Yanhong Zhu						
Group Art Unit	-1646 1614						
Examiner Name	Not yet Assigned LESCIFA. ROVIDS						
Attorney Docket Number	13131-0202 (44378/287574)						

		OTHER INFORMATION - NON PATENT LITERATURE DOCUMENTS	,
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T²
NAR	129	Agnese, et al., Clinical Biochemistry, Evaluation of Four Reagents for Delipidation of Serum, 16, 98-100. (1983)	
	130	Albouz, et al., Ann. Biol. Clin., Extraction of Plasma Lipids Preserving Antigenic Properties of Proteins and Allowing	
LAR		Quantitation of Gangliosides by Neuraminic Acid Determination, 37, 287-290. (abstract only) (1979)	
	131	Andre et al., Journal of Virology, Characterization of Low- and Very-Low-Density Hepatitis C Virus RNA-Containing Particles,	
LAL		76 (14), 6919-6928. (July 2002)	
	132	Asztalos et al., Arterioscler. Thromb. Vasc. Biol., Distribution of Apo A-I-Containing HDL Subpopulations in Patients with	
HAR		Coronary Heart Disease, 2670-2676. (December 1, 2000)	
	133	Asztalos et al., Arterioscler. Thromb. Vasc. Biol., Presence and Formation of 'Free Apolipoprotein A-I-Like' Particles in Human	
LAR	•	Plasma, 15, 1419-1423. (1995)	
UAL	134	Asztalos et al., Arterioscler. Thromb. Vasc. Biol., Role of Free Apolipoprotein A-I in Cholesterol Efflux, 17, 1630-1636. (1997)	
	135	Badimon, et al., Laboratory Investigation, High Density Lipoprotein Plasma Fractions Inhibit Aortic Fatty Streaks in	
LAR		Cholesterol-Fed Rabbits, 60, 455-461. (1989)	
	136	Badimon, et al., J. Clinical Investigation, Regression of Atherosclerotic Lesions by High Density Lipoprotein Plasma Fraction in	
LAL		the Cholesterol-Fed Rabbit, 85, 1234-1241. (1990)	
	.137	Barrans et al., Biochimica et Biophysica Acta, Pre-\$ HDL: Structure and Metabolism, 1300, 73-85. (1996)	
LAL			
	138	Bloom, et al., Clin. Blochem., Quantitation of lipid profiles from isolated serum lipoproteins using small volumes of human	
WAR		serum , 14, 119-125. (abstract only) (June 1981)	
	139	Cham, Clinical Chemistry, Nature of the Interaction Between Low-Density Lipoproteins and Polyanions and Metal Ions, as	
LAK		Exemplified by Heparin and Ca ^{2*} , 22, 1812-1816. (1976)	
1 0 0	140	Cham, et al., J. of Lipid Research, A Solvent System for Delipidation of Plasma or Serum Without Protein Precipitation, 17,	,
LAR		176-181. (1976)	
1.00	141	Cham, et al., Clinical Chemistry, Changes in Electrophoretic Mobilities of α- and β-Lipoproteins as a Result of Plasma	
UAK		Delipidation, 22, 305-309. (1976)	

Examiner Signature Date Considered 16 JULY 07

'Unique citation designation number. 'Applicant is to place a check mark here if English language translation is attached.

Approved for use through 10/31/2002 OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

			Complete if Known			
Substitute	for Form 1449/A/PTO		Application Number	10/650,110		
	NICODMATIO	N DIGGL OCUDE	Filing Date	August 26, 2003		
		N DISCLOSURE	First Named Inventor	Yanhong Zhu		
ů ·	STATEMENT	BY APPLICANT	Group Art Unit	1646 1614		
	(use as many s	heets as necessary	Examiner Name	Not yet Assigned LESUE A.ROYDS		
Sheet	[6] of	[9	Attorney Docket Number	13131-0292 (44378/287574)		

		OTHER INFORMATION - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	142	Cham, et al., Biochemical and Biophysical Research Communications, Heterogeneity of Lipoprotein B, 103, 196-206. (1981)	
LAR			
	143	Cham, et al., Chem. Biol. Interactions, Importance of Apolipoproteins in Lipid Metabolism, 20, 263-277. (1978)	
LAR			
	144	Cham, et al., J. Biol. Chem., In Vitro Partial Relipidation of Apolipoproteins in Plasma, 251, 6367-6371. (abstract only) (1976)	
LAR			
	145	Cham, et al., Pharmacol. (Life Sci. Adv.), Lipid Apheresis in an Animal Model Causes Acute Reduction in plasma Lipid	
LAR		Concentrations and Mobilisation of Ligid from Liver and Aorta, 13, 25-32. (1994)	
	146	Cham, et al., J. Clin. Apheresis, Lipid Apheresis in an Animal Model Causes In Vivo Changes in Lipoprotein Electrophoretic	
UNR		Patterns, 11, 61-70. (1996)	′
NI A			<u> </u>
	147	Cham, et al., J. Clin. Apheresis, Lipid Apheresis: An In Vivo Application of Plasma Delipidation with Organic Solvents	
LAR		Resulting in Acute Transient Reduction of Circulating Plasma Lipids in Animals, 10, 61-69. (1995)	
	148	Cham, et al., Clinical Chemistry, Phospholipids in EDTA - Treated Plasma and Serum, 39, 2347-2348. (1993)	
MAR	}		
	149.	Cham, et al., 59th Congress European Atherosclerosis Society, Nice, France, Rapid Regression of Atherosclerosis by	
VAL		Cholesterol Apheresis - A Newly Developed Technique, 17-21. (abstract only) (May 1992)	
	150	Cham, et al., Clinica Chimica Acta, Rapid, Sensitive Method for the Separation of Free Cholesterol from Ester Cholesterol, 49,	
LAL		109-113. (1973)	
	151	Collet et al., Journal of Biological Chemistry, Differential Effects of Lecithin and Cholesterol on the Immunoreactivity and	
LATE		Confirmation of Apolipoprotein A-I in High Density Lipoproteins, 266 (14), 9145-9152. (May 15, 1991)	
	152	Cruzado et al., Analytical Biochemistry, Characterization and Quantitation of the Apoproteins of High-Density Lipoprotein by	
WAL		Capillary Electrophoresis, 14 (7), 100-109. (1996)	
	153	Deva, et al., J. Hosp. Infect., Establishment of an in-use testing method for evaluating disinfection of surgical instruments using	
LAR		the duck hepatitis B model , 22, 119-130. (abstract only) (June 1996)	
·	154	Dwivedy, 18th Australian Atherosclerosis Society Conference, Surfers Paradise, Increase of Reverse Cholesterol Transport by	\top
WAR		Cholesterol Apheresis Regression of Atherosclerosis, 21. (1992)	

Examiner Signature	/ V·V I / JK(I	andle	Date Considered	16JULY07
		<u> </u>		

'Unique citation designation number. 'Applicant'is to place a check mark here if English language translation is attached.

IDS Filed Aug. 18,2004

PTO/SB/08B (08-00)
Approved for use through 10/31/2002 OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number Complete if Known Substitute for Form 1449/A/PTO **Application Number** 10/650,110 Filing Date August 26, 2003 INFORMATION DISCLOSURE First Named Inventor Yanhong Zhu STATEMENT BY APPLICANT Group Art Unit 1646-1614 (use as many sheets as necessary Not yet Assigned LESUEA ROYCE **Examiner Name** 13131-0292 (44378/287574) Attorney Docket Number of Sheet 7 9

	OTHER INFORMATION - NON PATENT LITERATURE DOCUMENTS						
Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s),	T²					
155	Eisenhauer, et al, Klin Wochenschr (KWH), Selective Removal of Low Density Lipoproteins (LDL) by Precipitation at Low pH:						
	First Clinical Application of the HELP System, 65, 161-168. (1987)						
156	Fang, et al., 18th Australian Atherosclerosis Society Conference, Gold Coast, Australia, In Vivo Rapid Mobilization of Adipose						
Tissue by Lipid Apheresis - A Newly Developed Technique. (1992)							
157	Feinstone, et al., Infection and Immunity, Inactivation of Hepatits B Virus and Non-A, Non-B Hepatitis by Chloroform, 41, 816-						
	821. (August 1983)						
158	Hatch et al., Lipoprotein Analysis, Advances in Lipid Research, Practical Methods for Plasma Lipoprotein Analysis, 6, 1-68.						
	(1968)						
159	Horowitz, et al., Blood Coagulation and Fibrinolysis, Viral safety of solvent/detergent-treated blood products, 5, S21-S28.						
	(1994)						
160	Innerarity, et al., Biochemistry, Enhanced Binding by Cultured Human Fibroblasts of Apo-E-Containing Lipoproteins as						
	Compared with Low Density Lipoproteins, 17, 1440-1447. (1978)						
161	Jackson et al., Biochimica et Biophysica Acta, Isolation and Characterization of the Major Apolipoprotein from Chicken High						
	Density Lipoproteins, 420, 342-349. (1976)						
162	Klimov, et al., Kardologlia, Extraction of Lipids from Blood Plasma and Subsequent Introduction of Autologous Delipidized						
	Plasma into the Body as a Possible Means to Treat Atherosclerosis [translation], 18, 23-29. (1978)						
163	Kolzumi, et al., J. Lipid Research, Behavior of Human Apolipoprotein A-1: Phospho-Lipid and apoHDL: Phospholipid						
	Complexes In Vitro and After Injection into Rabbits, 29, 1405-1415. (1988)						
164	Kostner, et al., XI Internet Symp. on Drugs Affecting Lipid Metabolism, Italy, Increase of APO A1 Concentration in						
	Hypercholesteraemic Chickens after Treatment with a Newly Developed Extracorpreal Lipid Elimination, (May 13, 1992)						
165	Kostner, et al., European Journal of Clinical Investigation, Lecithin-cholesterol acyltransferase activity in						
	Normocholesterolaemic and Hypercholesterolaemic Roosters: Modulation by Lipid Apheresis, 27, 212-218. (May 7, 1997)						
166	Lupien, et al., Lancet (LOS), A New Approach to the Management of Familial Hypercholesterolaemia: Removal of Plasma-						
	Cholesterol Based on the Principle of Affinity Chromatography, 1, 1261-1265. (1976)						
167	Moya et al., Arteriosclerosis and Thrombosis, A Cell Culture System for Screening Human Serum for Ability to Promote						
	Cellufar Cholesterol Efflux, 14 (7), 1056-1065. (July 1994)						
	155 156 157 158 159 160 161 162 163 164	Include name of the author (in CAPITAL LETTERS), title of the article (when apposite, bitle of the file (book, magazine, pounds, serial, symposium, catelag, etc.), date, page(s), volume-issue number(s), poulisher, city and/or country where published Eisenhauer, et al., Klin Wochenschr (KWH), Selective Removal of Low Density Lipoproteins (LDL) by Precipitation at Low pH: First Clinical Application of the HELP System, 65, 161-168. (1987) 156 Fang, et al., 18th Australian Atherosclerosis Society Conference, Gold Coast, Australia, In Vivo Rapid Mobilization of Adipose Tissue by Lipid Apheresis - A Newly Developed Technique. (1992) 157 Feinstone, et al., Infection and Immunity, Inactivation of Hepatitis B Virus and Non-A, Non-B Hepatitis by Chloroform, 41, 816-821. (August 1983) 158 Hatch et al., Lipoprotein Analysis, Advances in Lipid Research, Practical Methods for Plasma Lipoprotein Analysis, 6, 1-68. (1968) 159 Horowitz, et al., Blood Coagulation and Fibrinolysis, Viral safety of solvent/detergent-treated blood products, 5, S21-S28. (1994) 160 Innerarity, et al., Blood Coagulation and Fibrinolysis, Viral safety of solvent/detergent-treated blood products, 5, S21-S28. (1994) 161 Jackson et al., Blochemistry, Enhanced Binding by Cultured Human Fibroblasts of Apo-E-Containing Lipoproteins as Compared with Low Density Lipoproteins, 17, 1440-1447. (1978) 162 Kilmov, et al., Blochimica et Biophysica Acta, Isolation and Characterization of the Major Apolipoprotein from Chicken High Density Lipoproteins, 420, 342-349. (1976) 163 Kolzumi, et al., J. Lipid Research, Behavior of Human Apolipoprotein A-1: Phospho-Lipid and apoHDL: Phospholipid Complexes In Vitro and After Injection into Rabbits, 29, 1405-1415. (1988) 164 Kostner, et al., Xi Internet Symp. on Drugs Affecting Lipid Metabolism, Italy, Increase of APO A1 Concentration in Hypercholesterolaemic And Hypercholesterolaemic And Hypercholesterolaemic Removal of Plasma-Cholesterol Based on the Principle of Affinity Chromatography, 1, 1261-1265. (1976)					

Examiner Signature	1	1	W.	(1)	Ill	LK	MIK	Date Considered	16 JULY 07

oplicant is to place a check mark here if English language translation is attached.

TDS Filed Aug. 18,2004

PTO/SB/08B (08-00)

Approved for use through 10/31/2002 OMB 0851-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

	. 011001 1110 1 0 0 0 0 1		Complete if Known				
Substitute	for Form 1449/A/PTO		Application Number	10/650,110			
	INICODRA A TI	AN DICCLOCUDE	Filing Date	August 26, 2003 Yanhong Zhu			
	-	ON DISCLOSURE	First Named Inventor				
	STATEMENT	T BY APPLICANT	Group Art Unit	1646-1614			
,	(use as man	y sheets as necessary	Examiner Name	Not yet Assigned LESUE A. ROYDS			
Sheet	8 (of 9	Attorney Docket Number	13131-0292 (44378/287574)			

		OTHER INFORMATION - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T²
LAIL	168	Ngu, Medical Hypotheses, Chronic Infections from the Perspective of Evolution: a Hypothesis, 42, 81-88. (1994)	
NAC	169	Ngu, Medical Hypotheses, Human Cancers and Viruses: A Hypothesis for Immune Destruction of Tumours Caused by Certain Enveloped Viruses Using Modified Viral Antigens, 39, 17-21. (1992)	
	170	Ngu, Medical Hypotheses, The viral envelope in the evolution of HIV: a hypothetical approach to inducing an effective immune	
NAC		response to the virus, 48, 517-521. (1997)	
LAC	171	Okazaki et al., Journal of Chromatography, Biomedical Applications, Improved High-Performance Liquid Chromatographic Method for the Determination of Apolopoproteins in Serum High-Density Lipoproteins, 430, 135-142. (1988)	
	172	Parker, et al., Proceedings of the National Academy of Sciences, Plasma High Density Lipoprotein is Increased in Man When	
WAR		Low Density Lipoprotein (LDL) is Lowered by LDL-Pheresis, 83, 777-781. (1986)	
LAYL	173	Paterno et al., Department of Clinical and Experimental Medicine, Reconstituted High-Density Lipoprotein Exhibits Neuroprotection in Two Rat Models of Stroke. (December 29, 2003)	
HAR	174	Robern et al., Experientia, The Application of Sodium Deoxycholate and Sephacryl-200 for the Delipidation and Separation of High Density Lipoproteins, 38, 437-439. (1982)	
LAN	175	Ryan, et al., Clinical Chemistry, An Improved Extraction Procedure for the Determination of Triglycerides and Cholesterol in Plasma or Serum, 13, 769-772. (1967)	
Mil	176	Scanu et al., Analytical Biochemistry, Solubility in Aqueous Solutions of Ethanol of the Small Molecular Weight Peptides of the Serum Very Low Density and High Density Lipoproteins: Relevance to the Recovery Problem During Delipidation of Serum Lipoproteins, 44, 576-588. (1971)	
MAR	177	Segrest et al., Journal of Biological Chemistry, A Detailed Molecular Belt Model for Apolipoprotein A-I in Discoidal High Density Lipoprotein, 274 (45), 31755-31758. (November 5, 1999)	
HAL	178	Slater, et al., J. of Lipid Research, A Comparison of Delipidated Sera Used in Studies of Sterol Synthesis by Human Mononuclear Leukocytes, 20, 413-416. (1979)	
LAR	179	Slater, et al., Atherosclerosis, The Effect of Delipidated High Density Lipoprotein on Human Leukocyte Sterol Synthesis, 35, 41-49. (1980)	

Examiner Signature Date Considered 16 JULY 07

'Unique citation designation number. 'Applicant is to place a check mark here if English language translation is attached.

TDS Filed Aug. 18, 2004
PTO/SB/08B (08-00)
Approved for use through 10/31/2002 OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE to a collection of information unless it contains a valid OMB control number

			Reduction Act of 1855, no persons are re	Complete if Known			
Substitute t	for Form 1449/A/F	OTO		Application Number	10/650,110		
		ATION	I DICCI OCUDE	Filing Date	August 26, 2003		
			N DISCLOSURE	First Named Inventor	Yanhong Zhu		
,	STATEM	IENT I	BY APPLICANT	Group Art Unit	-1646- 1614		
(use as many sheets as necessary				Examiner Name	Not yet Assigned LESLIEA. ROYOS		
Sheet	9	of	9	Attorney Docket Number	13131-0292 (44378/287574)		

		OTHER INFORMATION - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	Tż
بما	180	Thompson, et al., Lancet (LOS), Plasma Exchange in the Management of Homozygous Familial Hypercholesterolaemia, 1,	
WAL		1208-1211. (1975)	
	181	Williams, et al., Proc. Natl. Acad. Sci. USA, Low Density Lipoprotein Receptor-Independent Hepatic Uptake of a Synthetic,	
LAR	,	Cholesterol-Scavenging Lipoprotein: Implications for the Treatment of Receptor-Deficient Atherosclerosis, 85, 242-246. (1988)	
	182	Williams et al., Biochim. Biophys. Act., Uptake of Endogenous Cholesterol by a Synthetic Lipoprotein , 875 (2), 183-194.	
NATE		(February 12, 1986)	
	183	Wong, et al, Journal of Lipid Research, Retention of gangliosides in serum delipidated by diisopropyl ether-1-butanol	
MAK		extraction, 24, 666-669. (1983)	
.	184	Wormser, Henry, PSC3110 - Fall Semester 2002, Lipids.	
LAR.			
	185	Yokoyama, et al., Arteriosclerosis, Selective Removal of Low Density Lipoprotein by Plasmapheresis in Familial	
iAL	,		
M	,	Hypercholesterolemia, 5, 613-622. (1985)	
1 40 4	186	Zhang et al., Journal of Lipid Research, Characterization of phospholipids in a pre-alpha HDL: Selective Phospholipid Efflux	
WAR		with Apolipoprotein A-I , 39, 1601-1607. (1998)	
,			
!			
			- -
		\	
			L
		MIN / WI	
Examiner Signature		Date Considered 16 JULY 07	
2.8.70.0		1 Williams	
¹Unique ci	tation d	esignation number. ² Applicant is to place a check mark here if English language translation is attached.	
		·	

SEP 0 5 2006 SEP 0 5 2006

PTO/SB/08A (08-00)

SEP 0 5 2006

Approved for use through 10/31/2002 OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for Form 1449/A/PTO THORMARK OFFICE TRADEMARK

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary of 2

Sheet

Complete if Known						
Application Number	10/650,110					
Filing Date	August 26, 2003					
First Named Inventor	Yanhong Zhu					
Group Art Unit	-1646 biy					
Examiner Name	- Unknown LESCIE A.ROYDS					
Attorney Docket Number	13131-0292 (44378-287574)					

				U.S. PATENT DOCUMENT	S	
Examiner Initials	Cite No.	U.S. Patent		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
IAL	1	2,941,872		Pilo et al.	06-21-1960	-
NAC	2	4,397,747		Ikeda	08-09-1983	-
NAS	3	4,605,648		Price	08-12-1986	-
NAR	4	4,671,909		Torobin	06-09-1987	
100	5	5,529,933		Young et al.	06-25-1996	-
		ļ			- 	<u>/</u>
	<u> </u>	 				
	<u> </u>	 				<u> </u>
						•
	ļ <u>.</u>	ļ <u>.</u>				
	ļ			·		
	 					
	 	 				
,	1					

				FOR	EIGN PATENT DOCUMEN			
Examiner Initials	Cite No.1	Office ³	Foreign Patent Number ⁴	Document Kind Code ³ (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	т
LAR	6	GB	2051602		Steiner et al.	01-21-1981	-	丄
WAR_	7	wo	00/57995		Korngold	10-05-2000	_	
WAR	8	wo	02/00266		Cham	01-03-2002	\	
								Ţ
		$\perp \wedge$						+
	<u> </u>	1x ()	No 1	- // / -				丄
		\sqrt{V}	111.1	112			14	

Examiner Signature Date Considered 16JULY 07

'Unique citation designation number. See attached kinds of U.S. Patent Documents. Senter Office that issued the document, by the two-letter code (WIPO Standard ST.B). For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Shind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language translation is attached.

IDS Filed Sept. 5,2006

PTO/SB/08B (08-00)
Approved for use through 10/31/2002 OMB 0851-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for Form 1449/A/PTO

Sheet 2

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary

Cor	Complete if Known					
Application Number	10/650,110					
Filing Date	August 26, 2003					
First Named Inventor	Yanhong Zhu					
Group Art Unit	-1646 b14					
Examiner Name	- Unknown LESLIE A. ROYDS					
Attorney Docket Number	13131-0292 (44378-287574)					

		OTHER INFORMATION - NON PATENT LITERATURE DOCUMENTS]
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, senal, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	9	BAROUCH et al. "Eventual AIDS Vaccine Failure in a Rhesus Monkey by Viral Escape from Cytotoxic T Lymphocytes",	
LAR		Nature, January 17, 2002, pps. 335-339, Vol. 415.	
	10	CLAY et al., "Formation of Apolipoprotein-Specific High Density Lipoprotein Particles from Lipid-Free Apolipoproteins A-I and	
LAL		A-II, Biochemical Society, 1999, pps. 445-451, Vol. 337.	
	11	DURBIN et al., "The Effect of Apolipoprotein A-II on the Structure and Function of Apolipoprotein A-I in a Homogeneous	
100-		Reconstituted High Density Lipoprotein Particle, The Journal of Biological Chemistry", December 12, 1997, pps. 31333-31339,	
LAD		Volume 272, No. 50.	
	12	FEINBERG et al. AIDS Vaccine Models: Challenging Challenge Viruses, Nature Medicine, March 2002, pps. 208-210,	
LML		Volume 8, No. 3:.	
	13	FEINSTONE, et al. "Inactivation of Hepatitis B Virus and Non-A, Non-B Hepatitis by Chloroform, Infection and Immunity,	
WARL		August 1983, p. 816-821, Vol. 41, No. 2.	
	14	WALKER, et al. "Escape from the Immune System", Nature, September 21, 2000, 313-314, Vol. 47.	
LAR			
	15	WIKIPEDIA.com entry for "Cell Membrane." http://en.wikipedia.org/wiki/Cell_membrane - Accessed 2/14/06 . 3 pages.	
MAC			
			
Examiner Signature		Date Considered 16 JULY 07	
Unique ci	itation c	lesignation number. Applicant is to place a check mark here if English language translation is attached.	
•			

IDS Filed May 24, 2007

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO Complete if Known Application Number 10/650,110 INFORMATION DISCLOSURE Filing Date August 26, 2003 STATEMENT BY APPLICANT First Named Inventor ZHU, Yanhong 1614 Art Unit (Use as many sheets as necessary) Examiner Name ROYDS, Leslie A 13131-0292 (44378/287574) Attorney Docket Number Sheet of

			U.S. PATENT (DOCUMENTS	
Examiner	Cite	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevan
Initials *	No.1	Number - Kind Code ² (if known)	MM-DD-YYYY	Cited Boddine/ii	Passages or Relevant Figures Appear
MAR	1	US- 5,055,396	10-08-1991	Curtiss et al.	
		US-			<u></u>
		US-			· · · · · · · · · · · · · · · · · · ·
		US-			
		US-		T	
		US-			
•		US-		<u> </u>	
		US-		·	
	.	US-			
		US-			
-		US-			
	-	US-			

		FOREIGN	PATENT DOCU	MENTS		
Examiner Initials*	Cita	Foreign Patent Document		Name of Patentee or	Pages, Columns, Lines, Where Relevant	
	Cite No. ¹	Country Code ³ - Number ⁴ - Kind Code ⁵ (<i>if</i> MM-DD-YYYY		Applicant of Cited Document	Passages or Relevant Figures Appear	T [®]
				•	-	1
NAR	2	WO 03/000373 A1	01-03-2003	Lipid Sciences, Inc.		
		·				

Examiner Signature Considered *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant, applican

Date

16 JULY 07

This collection of information is required by 37 CFR 1.97 and 1.98. The Information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

IDS Filed May 24,2007

PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute	e for form 1449A/PTC)		Complete if Known				
	•			Application Number	10/650,110			
INFO	RMATION	DIS	CLOSURE	Filing Date	August 26, 2003			
STA	TEMENT B	ΥA	PPLICANT	First Named Inventor	ZHU, Yanhong			
• • • • • • • • • • • • • • • • • • • •				Art Unit .	1614			
	(Use as many she	ets as	necessary)	Examiner Name	ROYDS, Leslie A.			
Sheet	2	of	2	Attorney Docket Number	13131-0292 (44378/287574)			

•		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the Item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Т2
LAR	3	DASS, et al., "Apolipoprotein A-1, Phospholipid Vesicles, and Cyclodextrins as Potential Anti-Atherosclerotic Drugs: Delivery, Pharmacokinetics, and Efficy", Drug Delivery, 2000, pgs. 161-182, Vol. 7.	
WAL	4	ITO, et al., "Cholesterol-Sphingomyelin Interaction in Membrane and Apolipoprotein-Mediated Cellular Cholesterol Efflux", Journal of Lipid Research, 2000, pgs. 894-904, Vol. 41.	
UAR	5	KOSTNER, "Beyond LDL-Cholesterol or Enhancing Reverse Cholesterol Transport", pgs. 328-331. No date own lable	
LAR	6	SCANU, et al., "Solubility in Aqueous Solutions of Ethanol of the Small Molecular Weight Peptides of the Serum Lipoproteins", Analytical Biochemistry, 1971, pgs. 576-588, Vol. 44.	
NAR	7	TADEY, et al., "Chromatographic Techniques for the Isolation and Purification of Lipoproteins", Journal of Chromatography B., 1995, pgs. 237-253, Vol. 671.	
HR	8	TRICERRI, et al., "Interaction of Apolipoprotein A-1 in Three Different Conformations with Palmitoyl Oleoyl Phosphatidycholine Vesciles", Journal of Lipid Research, 2002, pgs. 187-197, Vol. 43.	

Date Considered 16JULY07 Examiner Signature US2000 10019282.1